课题基金 / 基金详情

Novel Tumor-selective Anticancer Agents

Novel Tumor-selective Anticancer Agents
新型肿瘤选择性抗癌药物
批准号:
6739779
负责人:
YUQIANG WANG
金额:
$14.6万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-03-01 至 2005-02-28

项目摘要

项目成果

YUQIANG WANG的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Recently, tumor cells have been found to selectively accumulate certain n-3 fatty acids such as cis-4,7,10,13,16,19-docosahexenoic acid (DHA). DHA-paclitaxel, a conjugate of DHA and paclitaxel, has a greatly increased therapeutic efficacy and reduced side effects in both experimental animals and patients compared to free paclitaxel. We have synthesized a proprietary DHA-camptothecin conjugate that showed remarkable antitumor activity in experimental animals. We have filed a provisional patent application covering this invention (US 60/401,195). The objectives of this proposal are to synthesize novel DHA camptothecin conjugates, evaluate their antitumor activity in vitro and in experimental animals. It is expected that the novel DHA conjugates will have increased antitumor efficacies and reduced toxic side effects.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Synthesis and Evaluation of Novel Antitumor Agents
  • 批准号:
    6689646
  • 项目类别:
  • 资助金额:
    $10.0万
  • 财政年份:
    2003
  • 负责人:
    YUQIANG WANG
  • 依托单位:
Novel NMDA Receptor-Binding Drugs for Ischemia/Stroke
  • 批准号:
    6550204
  • 项目类别:
  • 资助金额:
    $10.0万
  • 财政年份:
    2002
  • 负责人:
    YUQIANG WANG
  • 依托单位:
SYNTHESIS AND EVALUTATION OF CATIONIC ANTITUMOR AGENTS
  • 批准号:
    6420493
  • 项目类别:
  • 资助金额:
    $25.0万
  • 财政年份:
    2001
  • 负责人:
    YUQIANG WANG
  • 依托单位:
SYNTHESIS AND EVALUTATION OF CATIONIC ANTITUMOR AGENTS
  • 批准号:
    6288049
  • 项目类别:
  • 资助金额:
    $24.44万
  • 财政年份:
    2001
  • 负责人:
    YUQIANG WANG
  • 依托单位:
海外基金